Waltham, Mass., May 6,
2020 — Trinity Life Sciences,
a leader in global life sciences commercialization solutions, announced the
availability of its 2019 Trinity Drug
Index, a commercial analysis of 26 unique therapeutic agents approved in
2016. The Index shows several new trends in drug approvals and evaluates actual
commercial performance of novel drugs post-approval.
The Trinity Drug Index outlines key themes and emerging
trends in the industry as more targeted and innovative products emerge. Scoring
is based on a combination of clinical/therapeutic, commercial, and R&D
factors.
In one key finding, the
commercial performance of products approved in 2016 was more closely correlated
to their clinical/therapeutic value than in previous years. Dave Fitzhenry, Trinity
CEO, said, “This is an important finding, implying the launched drugs’
therapeutic value translated more directly into commercial performance than in
the past.”
Although the number of new therapeutic agents decreased from
the 50+ new entities in each of the previous two years, half of the 26 featured
in the 2019 report are biologic products, including novel nucleic acid and
cell-based therapies. Neurology products outpaced oncology in terms of percent
of total approvals, representing two of the five highest scoring products in
this year’s cohort, both for rare early onset neurologic indications.
Metabolics accounted for 15% of approvals, while oncology showed a relative decrease
from the previous year, from 30% to 15%. Infectious disease products saw an
uptick. The list also featured significantly more “first-launch” companies
compared to recent years. Four of them–Intercept, Sarepta, Acadia, and
Clovis–are profiled in the report.
Looking ahead to the 2020 Trinity Drug Index, which will
track the performance of novel drugs approved in 2017, analysts report that
approvals are back up, totaling 46 products. They cover a wide range of disease
areas, including 18 for orphan diseases and 15 first-in-class therapeutics.
For a copy of the report, you are invited to visit: The 2019 Trinity
Drug Index.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
| For more information: Elizabeth Marshall Trinity Life Sciences 781-577-6376 emarshall@trinitylifesciences.com |